Organization
Indianapolis, IN
18 abstracts
Abstract
WITHDRAWN: A phase II study analyzing pre-operative stereotactic radiosurgery followed by resection for patients with 1-4 brain metastases.Org: Simon Cancer Center, Indianapolis, IN, Department of Radiation Oncology, Indiana University School of Medicine, Department of Clinical Radiology and Imaging Sciences,
Abstract
Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.Org: Department of Urologic Sciences, Vancouver General Hospital, Canada, BC Cancer - Vancouver Centre, BC,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.Org: University of Wisconsin, Carbone Cancer Center, Madison, WI, Wigen Biomedicine Technology (Shanghai), University of Wisconsin Carbone Cancer Center,
Abstract
Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.Org: Mayo Clinic, Rochester, MN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indianapolis, IN, Scottsdale, AZ,
Abstract
Outcomes in STK11-, KEAP1-, and KRAS-mutant lung squamous cell carcinoma (LSCC) with use of immune checkpoint inhibitors (ICIs).Org: Indiana University Melvin and Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University – Purdue University Indianapolis, IU Simon Cancer Center,
Abstract
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.Org: Roswell Park Comprehensive Cancer Center, Buffalo, IL, Nykode Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa General Hospital,
Abstract
The Tempus TIME trial portal and clinical trial enrollment.Org: Memorial Care, Fountain Valley, CA, CanSino Biologics, OhioHealth, Columbus, OH,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors.Org: Indiana University – Purdue University Indianapolis, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indianapolis, IN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,
Abstract
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, IU Simon Comprehensive Cancer Center, Indianapolis, IN, Innovative Immunotherapy Alliance,
Abstract
Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals,
Abstract
The association of demographic factors and disease stage on palliative care (PC) referral rates and completion of advanced directives in a lung cancer (LC) patient population.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals, Indiana University School of Medicine Department of Medicine, IU Hematology/Oncology,
Abstract
A funder-based comparison of global oncology research led by NCI-designated cancer centers: Results from the 2021 Global Oncology Survey.Org: Center for Global Health, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Rockville, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,
Abstract
A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITISOrg: Eli Lilly and Company, San Diego Clinical Services, San Diego State University Department of Biology, San Diego, CA, United States of America, Csolnoky Ferenc Hospital,
Abstract
ANTIBODY RESPONSE TO TERIPARATIDE 20 MCG: TREATMENT AND FOLLOW-UPOrg: Clinical Research Centre, Statistics Division, Medical Communications, Eli Lilly and Company, Indianapolis, IN,